Immunohistopathological analyses identified the lesion as an isocitrate dehydrogenase (IDH) wild-type epithelioid glioblastoma with O6-methylguanine-DNA methyltransferase (MGMT) methylation at 12% and BRAF V600E mutation (Fig. 3). Here, BRAF is linked to glioblastoma.